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Purpose: Calcific aortic valve disease (CAVD) affects 2% to 6% of pop-
ulation over 65 years in industrialized countries. CAVD, assimilated to an
"atherosclerosis-like" disease, results from dysregulated mechanisms such as
fibrosis, inflammation and calcification. These mechanisms could be enhanced
by the osteoblastic differentiation of the valvular interstitial cells (VIC), the
most prevalent cell type in the human aortic valves. Leptin, known as the
product of obesity gene, has recently been linked to aortic valve calcification
in ApoE -/- mice. Our hypothesis is that leptin could play an important role in
the calcifying processes implicated in CAVD via direct effects on VIC pheno-
type in humans.
Methods: Expression of leptin and its receptor was analysed by RT-qPCR,
immunohistochemistry and ELISA in 74 human calcific aortic valves and in
10 normal valves. VIC isolated from calcific and normal aortic valves were
also analysed. The effects of leptin on the expression of osteoblastic markers
such as osteopontin, osteonectin, alkaline phosphatase, BMP-2 and BMP-7 in
cultured VIC were investigated.
Results: The presence of leptin and its long, functional, receptor isoform
(ObR-L) was observed in human aortic valves with an overexpression of
leptin in calcified vs non-calcified valvular zones (114.52 pg/mg (47.96-
234.55) vs 66.95 pg/mg (42.76-137.15), p<0.05). Moreover, ObR-L and leptin
were constitutively expressed in VIC with a higher ObR-L expression in VIC
isolated from pathological vs normal valves (p<0.05). Finally, stimulation of
VIC by leptin at physiological concentrations (20 to 100 ng/mL) significantly
increased osteonectin (pro-calcifying) and decreased BMP-7 (anti-calcifying)
expression levels.
Conclusion: Taken together, these novel findings suggest that leptin could
be involved in the process of human valve calcification by modifying VIC
phenotype.
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Chronic use of 5-HT2B receptor (5-HT2B-R) agonists (anorectic drugs or ergot
derivatives) has been associated with left cardiac valve injury but the mecha-
nisms are unclear. Lesions are characterised by increased thickness and cellu-
larity with massive extracellular matrix production. This work was designed to
study contribution of 5-HT2B and 5-HT2A-R and the link with their activation and
endothelial nitric oxide in valve degeneration. We validated an experimental
mouse model of valvulopathy by infusing (28 days; Alzet® pumps) the selective
5-HT2B-R agonist (nordexfenfluramine: NdF 1mg/kg/day) and designed
13 groups: 5 groups of WT mice (129svPas; 12 weeks): 1) control (C); 2) NdF;
3) NdF+ritanserine (2mg/kg/day); 4) NdF+SB206553 (1mg/kg/day); 5) NdF+L-
NAME (300mg/kg/day); 8 groups of transgenics: 6) 5-HT2B-/--C; 7) 5-HT2B-/--
NdF; 8) 5-HT2A/2B-/--C; 9) 5-HT2A/2B-/--NdF; 10) 5-HT2A-/--C and 11) 5-HT2A-/--
NdF and 2 groups of eNOS-/- mice 12) eNOS-/--C and 13) eNOS-/--NdF. Mice
were monitored for hemodynamic and echocardiographic parameters. At day 28,
blood 5-HT and urinary 5-HIAA concentrations were measured and hearts har-
vested for histological analysis. In controls, this analysis reveals mitral valve
lesions with increased thickness (WT-C 35±4μm vs WT-NdF 69±9μm; p<0,05)
and number of endothelial cells (+40%). Lesions are fully prevented by pharma-
cological and constitutive inactivation of: 5-HT2B-R (SB 206553 or 5-HT2B-/-
mice) and both 5-HT2A and 5-HT2B-R (ritanserine or 5-HT2A/2B-/-). In 5-HT2A-/-
treated with NdF, we still observe an increased valve thickness (5-HT2A-/--C
45±4μm vs 5-HT2A-/--NdF 60±8μm) mainly due to increased cellularity. Finally,
eNOS inhibition (L-NAME or eNOS-/- mice) also prevents lesions indicating the
crucial role of endothelial cells in 5-HT2B-mediated mitral valve degeneration. 
We demonstrate for the first time that both 5-HT2B and 5-HT2A-Rs are
involved in drug-induced valvulopathy and the role of endothelial cells and
eNOS activation.
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Heart valve diseases affect 3% of world population, and surgery is often
the only therapeutic mean. A genetic study performed on a family in which
several members exhibited a mitral valve prolapse (MVP) identified a muta-
tion on LRRFip1 gene. LRRFip1 undergoes extensive alternative transcription
splicing giving rise to five isoforms in humans and the mutation we identified
results in R94G substitution in three (Iso1, 3 and 4) out of the five isoforms.
Previous studies essentially focused on LRRFip1-Iso5 that was first described
as a transcription factor interacting with positive (Dishevelled) and negative
(Flightess-1) regulators of the canonical Wnt b-catenin dependent pathway.
LRRFip1 thus appeared as an interesting gene in MVP as it may participate
and regulate two crucial events of cardiac valve development and homeostasis
involving Wnt pathway: epithelial to mesenchymal transition and cell prolif-
eration. Interestingly, we showed using RNA sequencing analysis and RT-
PCR experiments that LRRFip1-Iso1 is the most expressed isoform in human
valves. Furthermore, LRRFip1-Iso1 has poor homology with the other iso-
forms and nothing is known about its function. We thus focused on LRRFIP1-
Iso1 and analyzed its cellular localization, its role in Wnt pathway and the
impact of R94G mutation in HEK293 cells. Cell fractionation experiments
revealed a nuclear localization of LRRFip1-Iso1 while other isoforms are
strictly cytoplasmic. We then showed by Luciferase assays and co-immuno-
precipitations that out of the five isoforms, LRRFip1-Iso1 activates the canon-
ical Wnt pathway at the highest levels and interacts mainly with Fli-1.
Furthermore, R94G mutation decreases this interaction. Thus, our studies sug-
gest that LRRFip1-Iso1 may activate the canonical Wnt pathway by opposing
Fli-1 inhibitory effects. R94G mutation may alter this key regulatory loop,
deregulate gene transcription and consequently alter valvulogenesis and/or
valve homeostasy. 
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The mitral valve prolapse (MVP) affects about 3% of the population and
remains one of the most common indications for valvular surgery. Although
the genetic basis of MVP is acknowledged since we identified FLNA
(Filamin-A; FlnA) as the first gene responsible for this life threatening dis-
ease, the genes involved and identified remain scarce. To identify new genes
and genetic variants, we performed whole exome sequencing of 20 familial
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cases of isolated MVP. In a family suffering a mild form of MVP, we found
a non-synonymous rare variant in the Rac1 specific GTPase Activating Pro-
tein ARHGAP24 gene encoding ARHGAP24-D92N mutant protein. Interest-
ingly, ARHGAP24 protein was previously shown to interact with FlnA and
was thus named FilGAP. Also, our previous studies established the potential
involvement of FilGAP and small GTPases (RhoA, Rac1) in FlnA-associated
MVP. Complete exon sequencing of ARHGAP24 in 95 additional MVP
patients identified, according to genetic databases, 3 other non-synonymous
rare sequence variations encoding FilGAP-R95Q; P417H and T481M mutants.
Based on this genetic analysis, HEK293 cells were used to analyze the effects
of theses mutations. The role of FilGAP is to decrease Rac1 activity and we
showed that all the mutations identified are loss of function mutations mutated
leading to increase Rac1 activity. Increased spreading of mutant FilGAP
expressing cells corroborates this increase in Rac activity. In addition, we
showed FlnA poorly co-immunoprecipitates FilGAP-P417H and T481M sug-
gesting reduced FlnA/FilGAP interaction might be the molecular mechanism
responsible for the loss of function of these two mutations. The molecular
mechanism involved for the two other mutations (R92Q and D92N) is under
investigations. Together, we identified a new gene involved, like FlnA, in cel-
lular mechanical stress response pathway suggesting common physiopatholog-
ical mechanisms are at work in FilGAP and FlnA associated valvulopathy.
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Many compounds (pergolide, cabergoline, fenfluramine, ectasy) were
described as inducers of fibrotic valvular lesions, a rare but severe drug reac-
tion. All these drugs share in common the pharmacological property to acti-
vate a serotonergic receptor subtype, the 5HT2B. Together with the well
known “carcinoid heart” that is a valvulopathy due to high amounts of circu-
lating serotonin, these observations lead to the hypothesis that cardiac valves
express a "serotonergic system" that could be activated by 5-HT or 5-HTR
agonists. The aim of this work was to characterize the pattern of expression of
5-HT2A,2B,4 receptors, the serotonin transporter (SERT) and the biosynthesis
peripheral enzyme (Tph1) in various valvulopathies. Thirty degenerated
human valves were collected: 11 calcified aortic valves (CAV), 5 sclerotic
aortic valves (SAV), 11 dystrophic mitral valves (DMV). They were analyzed
by RT-qPCR and immunohistochemistery. All samples express 5HT2A,2B,4
receptors, SERT and Tph1. In these valve tissues, the amount of 5HT2B
receptor (5HT2B R) mRNA is higher than the 5HT2A one (5HT2A R) : Δ Ct
(5HT2B R -18S) = 12,53±1,12 vs Δ Ct (5HT2A R -18S) = 15,95±2,37 for
CAV, Δ Ct (5HT2B R -18S) = 13,04±2,62 vs Δ Ct (5HT2A R -
18S)=16,00±1,46 for SAV, Δ Ct (5HT2B R -18S) = 12,34±0,77 vs Δ Ct
(5HT2A R -18S) = 16,14±0,86 for DMV. The amounts of SERT, Tph1 and
5HT4 receptor mRNA are negligible whatever valve and etiology. At a topo-
graphical point of view, 5HT2BR expression is found in endothelial cells (at
the valve surface) but also inside valve lesions, by interstitial cells (smooth
muscle α-actin and vimentin positive cells) located in an abundant glycosami-
noglycan matrix. Characterization of these cells is in progress. In particular,
we characterize the high amount CD34+ hematopoietic progenitors that are
highly present in fibromyxoid lesions. To summarize, 5HT2A,2B,4 receptors,
SERT and Tph1 are expressed in aortic and mitral diseased valves. The
amounts of 5HT2A,2B R mRNA are equal between mitral and aortic valves.
The contribution of the two 5-HT2 receptors in valve degeneration is now
under investigation whatever the pathological process considered.
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Purpose: Aortic Valve Stenosis (AVS) affects 2% to 6% of population
over 65 years in industrialized countries. This atherosclerosis-like pathology
involves Valve Interstitial Cell (VIC) proliferation and commitment to osteo-
blast-like cells. This prevalent cell type of aortic valve presents five identifi-
able phenotypes: embryonic progenitor endothelial/mesenchymal cells,
progenitor, quiescent, activated and osteoblastic VICs. To study the patho-
physiology of AVS, their in vitro cultures are frequently used. Our purpose is
to characterize VICs isolated from normal and fibrocalcified human aortic
valves and analyze their in vitro behavior.
Methods: We collected 5 normal and 5 fibrocalcified human aortic valves.
VICs were isolated by collagenase digestion. Characterization is assessed at
different passages (2 to 5) by immunofluorescence. Analyzed markers consist
of progenitor cell markers (SSEA4, ABCG2, CD90, NG2 and OsteoBlast
CaDHerin (OB-CDH)), fibroblast markers (vimentin and HSP47) and smooth
muscle cell (SMC) marker (α-actin). By blue trypan and MTS, we compared
the viability and proliferation of VICs in standard and starvation medium at
48 hours.
Results: Independently of their origin, VICs express all progenitor cell
markers. Fibroblasts markers are expressed twice more by pathological VICs
and four times more for SMC marker. In standard medium, VICs viability is
similar (96,7±2,4 % vs 96,4±2,3 % ; normal vs pathological ± SEM). Patho-
logical VICs proliferate more than normal VICs (2,2±0,7 vs 1,6±0,4 ; OD/OD
control). In starvation medium, viability is significantly reduced for patholog-
ical VICs (89,6±7,9 % vs 76,5±5,3 %) but still proliferate in opposition with
normal VICs (1,7±0,6 vs 1,2±0,3).
Conclusion: All VICs phenotypes are found in vitro with no culture selec-
tion but in different ratios according to their origin. These new data in VICs
isolated from normal or pathological human aortic valves allow us to approve
their use in vitro.
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